Search Results - "BENYUNES, Mark"

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study by Swain, Sandra M, Dr, Kim, Sung-Bae, MD, Cortés, Javier, MD, Ro, Jungsil, MD, Semiglazov, Vladimir, MD, Campone, Mario, MD, Ciruelos, Eva, MD, Ferrero, Jean-Marc, MD, Schneeweiss, Andreas, MD, Knott, Adam, PhD, Clark, Emma, MSc, Ross, Graham, FFPM, Benyunes, Mark C, MD, Baselga, José, MD

“…Summary Background CLEOPATRA is a phase 3 study to compare the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and…”
Get full text

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer by Swain, Sandra M, Baselga, José, Kim, Sung-Bae, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Heeson, Sarah, Clark, Emma, Ross, Graham, Benyunes, Mark C, Cortés, Javier

“…In a randomized trial comparing pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel, the pertuzumab combination resulted in a…”
Get full text

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer by Baselga, José, Cortés, Javier, Kim, Sung-Bae, Im, Young-Hyuck, Im, Seock-Ah, Hegg, Roberto, Roman, Laslo, Pedrini, José Luiz, Pienkowski, Tadeusz, Knott, Adam, Clark, Emma, Benyunes, Mark C, Ross, Graham, Swain, Sandra M

“…Pertuzumab, an anti-HER2 antibody, recognizes a different epitope of HER2 than does trastuzumab and behaves differently. In patients with metastatic breast…”
Get full text

Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study by Swain, Sandra M., Ewer, Michael S., Cortés, Javier, Amadori, Dino, Miles, David, Knott, Adam, Clark, Emma, Benyunes, Mark C., Ross, Graham, Baselga, José

“…Introduction. We report cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel observed in the phase…”
Get full text

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer by Quartino, Angelica L., Li, Hanbin, Jin, Jin Y., Wada, D. Russell, Benyunes, Mark C., McNally, Virginia, Viganò, Lucia, Nijem, Ihsan, Lum, Bert L., Garg, Amit

“…Purpose The NeoSphere trial evaluated pertuzumab in the neoadjuvant setting [early breast cancer (EBC)] with pathological complete response (pCR) as the…”
Get full text

Neutropenia in Patients Treated with Rituximab by Voog, Eric, Morschhauser, Franck, Solal-Céligny, Philippe

“…To the Editor: Rituximab is effective in B-cell lymphomas either as a single agent or combined with chemotherapy. Its toxic effects are generally mild and…”
Get full text

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer by Swain, Sandra M., Baselga, José, Kim, Sung-Bae, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Heeson, Sarah, Clark, Emma, Ross, Graham, Benyunes, Mark C., Cortés, Javier

Get full text

Interstitial Pneumonitis Related to Rituximab Therapy by Burton, Catherine, Kaczmarski, Richard, Jan-Mohamed, Riaz

“…To the Editor: Rituximab targets CD20+ B cells. It is used increasingly for the treatment of B-cell non-Hodgkin's lymphoma, alone or in combination with…”
Get full text

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer by Baselga, José, Cortés, Javier, Kim, Sung-Bae, Im, Seock-Ah, Hegg, Roberto, Im, Young-Hyuck, Roman, Laslo, Pedrini, José Luiz, Pienkowski, Tadeusz, Knott, Adam, Clark, Emma, Benyunes, Mark C., Ross, Graham, Swain, Sandra M.

Get full text

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial by STEWART, A. Keith, VESCIO, Robert, STIFF, Pat, MEHARCHARD, Jacinta, SCHLOSSMAN, Robert, BROWN, Randy, TULLY, Heather, BENYUNES, Mark, JACOBS, Cindy, BERENSON, Ronald, WHITE, Michael, DIPERSIO, John, SCHILLER, Gary, ANDERSON, Kenneth C, BERENSON, James, BALLESTER, Oscar, NOGA, Stephen, RUGO, Hope, FREYTES, Cesar, STADTMAUER, Edward, TARANTOLO, Stefano, SAHEBI, Firoozeh

“…Although high-dose chemotherapy supported by autologous peripheral-blood progenitor-cell (PBPC) transplantation improves response rates and survival for…”
Get full text

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer by von Minckwitz, Gunter, Procter, Marion, de Azambuja, Evandro, Zardavas, Dimitrios, Benyunes, Mark, Viale, Giuseppe, Suter, Thomas, Arahmani, Amal, Rouchet, Nathalie, Clark, Emma, Knott, Adam, Lang, Istvan, Levy, Christelle, Yardley, Denise A, Bines, Jose, Gelber, Richard D, Piccart, Martine, Baselga, Jose

“…In this trial, the addition of pertuzumab to trastuzumab and chemotherapy in early-stage HER2-positive breast cancer improved the rate of invasive-disease–free…”
Get full text

No clinical evidence for CD4+ cell depletion caused by rituximab by Saville, M. Wayne, Benyunes, Mark C., Multani, Pratik S.

Get full text

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study by Kuemmel, Sherko, Tondini, Carlo A., Abraham, Jacinta, Nowecki, Zbigniew, Itrych, Bartosz, Hitre, Erika, Karaszewska, Bogusława, Juárez-Ramiro, Alejandro, Morales-Vásquez, Flavia, Pérez-García, Jose Manuel, Cardona-Huerta, Servando, Monturus, Estefania, Sequi, Marco, Restuccia, Eleonora, Benyunes, Mark, Martín, Miguel

“…Purpose Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC)…”
Get full text

Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study by Kümmel, Sherko, Tondini, Carlo A, Abraham, Jacinta, Nowecki, Zbigniew, Itrych, Bartosz, Hitre, Erika, Karaszewska, Bogusława, Juarez, Alejandro, Morales-Vásquez, Flavia, García, Jose Manuel Pérez, Cardona-Huerta, Servando, Benyunes, Mark, Restuccia, Eleonora, Knott, Adam, Monturus, Estefanía, Sequi, Marco, Martín, Miguel

“…Background Previous trials showed that fixed-dose subcutaneous trastuzumab and hyaluronidase-oysk (Herceptin Hylecta™; H SC) was non-inferior to weight-based…”
Get full text

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC) by Swain, Sandra M., Miles, David, Kim, Sung-Bae, Im, Young-Hyuck, Im, Seock-Ah, Semiglazov, Vladimir, Ciruelos, Eva, Schneeweiss, Andreas, Monturus, Estefania, Clark, Emma, Knott, Adam, Restuccia, Eleonora, Benyunes, Mark, Cortes, Javier

“…Abstract only 1020 Background: Progression-free and overall survival (PFS and OS) were significantly improved with 1L P + H + D v Pla + H + D in 808 pts with…”
Get full text

APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC) by Von Minckwitz, Gunter, Procter, Marion Jennifer, De Azambuja, Evandro, Zardavas, Dimitrios, Knott, Adam, Viale, Giuseppe, Suter, Thomas M., Arahmani, Amal, Rouchet, Nathalie, Clark, Emma, Benyunes, Mark, Lang, Istvan, Levy, Christelle, Yardley, Denise A., Bines, Jose, Gelber, Richard D., Piccart-Gebhart, Martine J., Baselga, Jose

“…Abstract only LBA500 Background: In previous trials P significantly prolonged progression free and overall survival and increased pCR rates when added to T+C…”
Get full text

APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC) by Von Minckwitz, Gunter, Procter, Marion Jennifer, De Azambuja, Evandro, Zardavas, Dimitrios, Knott, Adam, Viale, Giuseppe, Suter, Thomas M., Arahmani, Amal, Rouchet, Nathalie, Clark, Emma, Benyunes, Mark, Lang, Istvan, Levy, Christelle, Yardley, Denise A., Bines, Jose, Gelber, Richard D., Piccart-Gebhart, Martine J., Baselga, Jose

“…Abstract only LBA500 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual…”
Get full text

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study by Ewer, Michael, Baselga, José, Clark, Emma, Benyunes, Mark, Ross, Graham, Swain, Sandra M.

“…Abstract only 533^ Background: Addition of trastuzumab (T) to chemotherapy has transformed outcomes in pts with HER2-positive breast cancer. In pts who had…”
Get full text

Concordance between independently and investigator-assessed progression-free survival in CLEOPATRA by Miles, David, Swain, Sandra M., Im, Young-Hyuck, Knott, Adam, Ross, Graham, Clark, Emma, Benyunes, Mark, Baselga, José

“…Abstract only e11055^ Background: In CLEOPATRA, pertuzumab (P) + trastuzumab (T) + docetaxel (D) was compared to placebo (Pla)+T+D in HER2-positive 1 st -line…”
Get full text

Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study by Swain, Sandra M., Kim, Sung-Bae, Cortés, Javier, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Knott, Adam, Clark, Emma, Ross, Graham, Benyunes, Mark C., Baselga, José

Get full text